Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey
We conducted a national in-depth analysis including pharmacovigilance reports and clinical study to assess the reporting rate (RR) and to determine the clinical profile of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in COVID-19-vaccinated individuals. First, based on the French pharm...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2334084 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849717017460867072 |
|---|---|
| author | Pierre-André Jarrot Adrien Mirouse Sébastien Ottaviani Simon Cadiou Jean-Hugues Salmon Eric Liozon Simon Parreau Martin Michaud Benjamin Terrier Pierre-Edouard Gavand Ludovic Trefond Virginie Lavoiepierre Jeremy Keraen Daniel Rekassa Bastien Bouldoires Thierry Weitten Damien Roche Antoine Poulet Caroline Charpin Vincent Grobost Marion Hermet Magali Pallure Chloe Wackenheim Ludovic Karkowski Pierre Grumet Thomas Rogier Nabil Belkefi Vincent Pestre Emilie Broquet Amélie Leurs Sophie Gautier Valérie Gras Pierre Gilet Jan Holubar Nadia Sivova Nicolas Schleinitz Jean-Marc Durand Brice Castel Alexandre Petrier Robin Arcani Baptiste Gramont Philippe Guilpain Hubert Lepidi Pierre-Jean Weiller Joelle Micallef David Saadoun Gilles Kaplanski |
| author_facet | Pierre-André Jarrot Adrien Mirouse Sébastien Ottaviani Simon Cadiou Jean-Hugues Salmon Eric Liozon Simon Parreau Martin Michaud Benjamin Terrier Pierre-Edouard Gavand Ludovic Trefond Virginie Lavoiepierre Jeremy Keraen Daniel Rekassa Bastien Bouldoires Thierry Weitten Damien Roche Antoine Poulet Caroline Charpin Vincent Grobost Marion Hermet Magali Pallure Chloe Wackenheim Ludovic Karkowski Pierre Grumet Thomas Rogier Nabil Belkefi Vincent Pestre Emilie Broquet Amélie Leurs Sophie Gautier Valérie Gras Pierre Gilet Jan Holubar Nadia Sivova Nicolas Schleinitz Jean-Marc Durand Brice Castel Alexandre Petrier Robin Arcani Baptiste Gramont Philippe Guilpain Hubert Lepidi Pierre-Jean Weiller Joelle Micallef David Saadoun Gilles Kaplanski |
| author_sort | Pierre-André Jarrot |
| collection | DOAJ |
| description | We conducted a national in-depth analysis including pharmacovigilance reports and clinical study to assess the reporting rate (RR) and to determine the clinical profile of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in COVID-19-vaccinated individuals. First, based on the French pharmacovigilance database, we estimated the RR of PMR and GCA cases in individuals aged over 50 who developed their initial symptoms within one month of receiving the BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines. We then conducted a nationwide survey to gather clinical profiles, therapeutic management, and follow-up data from individuals registered in the pharmacovigilance study. A total of 70 854 684 COVID-19 vaccine doses were administered to 25 260 485 adults, among which, 179 cases of PMR (RR 7. 1 cases/1 000 000 persons) and 54 cases of GCA (RR 2. 1 cases/1 000 000 persons) have been reported. The nationwide survey allowed the characterization of 60 PMR and 35 GCA cases. Median time to the onset of first symptoms was 10 (range 2–30) and 7 (range 2–25) days for PMR and GCA, respectively. Phenotype, GCA-related ischemic complications and -large vessel vasculitis as well as therapeutic management and follow-up seemed similar according to the number of vaccine shots received and when compared to the literature data of unvaccinated population. Although rare, the short time between immunization and the onset of first symptoms of PMR and GCA suggests a temporal association. Physician should be aware of this potential vaccine-related phenomenon. |
| format | Article |
| id | doaj-art-970ddb7d49c04bd4a900d1b8a0d87da2 |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-970ddb7d49c04bd4a900d1b8a0d87da22025-08-20T03:12:47ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2334084Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide surveyPierre-André Jarrot0Adrien Mirouse1Sébastien Ottaviani2Simon Cadiou3Jean-Hugues Salmon4Eric Liozon5Simon Parreau6Martin Michaud7Benjamin Terrier8Pierre-Edouard Gavand9Ludovic Trefond10Virginie Lavoiepierre11Jeremy Keraen12Daniel Rekassa13Bastien Bouldoires14Thierry Weitten15Damien Roche16Antoine Poulet17Caroline Charpin18Vincent Grobost19Marion Hermet20Magali Pallure21Chloe Wackenheim22Ludovic Karkowski23Pierre Grumet24Thomas Rogier25Nabil Belkefi26Vincent Pestre27Emilie Broquet28Amélie Leurs29Sophie Gautier30Valérie Gras31Pierre Gilet32Jan Holubar33Nadia Sivova34Nicolas Schleinitz35Jean-Marc Durand36Brice Castel37Alexandre Petrier38Robin Arcani39Baptiste Gramont40Philippe Guilpain41Hubert Lepidi42Pierre-Jean Weiller43Joelle Micallef44David Saadoun45Gilles Kaplanski46Department of Internal Medicine and Clinical Immunology, Hôpital de La Conception, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, FranceDepartment of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l’Amylose inflammatoire (CEREMAIA), Sorbonne Universités, Paris, FranceDepartment of Rheumatology, DMU Locomotion, Hôpital Bichat-Claude Bernard, APHP, Université de Paris, Paris, FranceDepartment of Rheumatology, CHU de Rennes, Université de Rennes 1, Rennes, FranceDepartment of Rheumatology, Hôpital de La Maison Blanche, Université de Reims, Reims, FranceDepartment of Internal Medicine, Hôpital Universitaire de Limoges, Limoges, FranceDepartment of Internal Medicine, Hôpital Universitaire de Limoges, Limoges, FranceDepartment of Internal Medicine, Clinique Saint-Exupery, Toulouse, FranceNational Referral Center for Rare Systemic Autoimmune Disease, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP), Centre, Université Paris Cité, Paris, FranceDepartment of Internal Medicine, Clinique Rhena, Strasbourg, FranceDepartment of Internal Medicine, Hôpital Gabriel Montpied, Clermont-Ferrand, FranceDepartment of Internal Medicine and Clinical Immunology, Hôpital de La Conception, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, FranceDepartment of Internal Medicine, Hôpital de Cornouaille, Quimper, FranceDepartment of Rehabilitation, Centre Thermal, Greoux Les Bains, FranceDepartment of Internal Medicine, Hôpital Louis Pasteur, Colmar, FranceDepartment of Internal Medicine, Hôpital des Alpes du Sud, Gap, FranceDepartment of Rheumatology, Hôpital Saint-Joseph, Marseille, FranceDepartment of Internal Medicine, Hôpital Saint-Joseph, Marseille, FranceDepartment of Rheumatology, Hôpital Saint-Joseph, Marseille, FranceDepartment of Internal Medicine, Hôpital Estaing, Clermont-Ferrand, FranceDepartment of Internal Medicine, Hôpital de Vichy, Vichy, FranceDepartment of Rheumatology, Hôpital de Cannes Simone Veil, Cannes, FranceDepartment of Internal Medicine, Medipole Hôpital Privé, Villeurbanne, FranceDepartment of Internal Medicine, Hôpital d’Instruction des Armées Sainte-Anne, Toulon, FranceDepartment of Internal Medicine, Hôpital des Alpes du Sud, Gap, FranceDepartment of Internal Medicine and Systemic Disease, Hôpital François Mitterand, Dijon, FranceDepartment of Internal Medicine, CH de Melun, Melun, FranceDepartment of Internal Medicine and Infectious Disease, CH d’Avignon, Avignon, FranceGeneral Practitioner, Bordeaux, FranceDepartment of Internal Medicine and Infectious Disease, CH de Dunkerque, Dunkerque, FranceDepartment of Pharmacology, centre régional de pharmacovigilance Nord Pas de Calais, CHRU de Lille, Lille, FranceDepartment of Clinical Pharmacology, Centre régional de pharmacovigilance, service de pharmacologie clinique, CHU Amiens-Picardie, Amiens, FranceRegional Center of Pharmacovigilance, CHRU de Nancy, Hôpital Central, Nancy, FranceDepartment of Internal Medicine, CHU de Nîmes, Nîmes, FranceDepartment of Internal Medicine, CH de Tourcoing, Tourcoing, FranceDepartment of Internal Medicine, Hôpital de La Timone, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, FranceDepartment of Internal Medicine, Hôpital de La Timone, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, FranceDepartment of Internal Medicine, CH de Tarbes, Tarbes, FranceGeneral Practitioner, Roquebrune sur Argens, FranceDepartment of Internal Medicine and Therapeutics Department, Hôpital de La Timone, Marseille, FranceDepartment of Internal Medicine, CHU de Saint-Etienne, Saint-Etienne, FranceDepartment of Internal Medicine, CHU Saint-Eloi, Montpellier, FrancePathological Laboratory, Hôpital de La Timone, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, FranceDepartment of Onco-Hematology, Institut Paoli-Calmettes, Marseille, FranceDepartment of Clinical Pharmacology and pharmacosurveillance, Regional Pharmacovigilance Center of Marseille, Hôpital de La Timone, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, FranceDepartment of Internal Medicine and Clinical Immunology, Centre de Référence des Maladies Auto-Immunes Systémiques Rares, Centre de Référence des Maladies Auto-Inflammatoires et de l’Amylose inflammatoire (CEREMAIA), Sorbonne Universités, Paris, FranceDepartment of Internal Medicine and Clinical Immunology, Hôpital de La Conception, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, FranceWe conducted a national in-depth analysis including pharmacovigilance reports and clinical study to assess the reporting rate (RR) and to determine the clinical profile of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in COVID-19-vaccinated individuals. First, based on the French pharmacovigilance database, we estimated the RR of PMR and GCA cases in individuals aged over 50 who developed their initial symptoms within one month of receiving the BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines. We then conducted a nationwide survey to gather clinical profiles, therapeutic management, and follow-up data from individuals registered in the pharmacovigilance study. A total of 70 854 684 COVID-19 vaccine doses were administered to 25 260 485 adults, among which, 179 cases of PMR (RR 7. 1 cases/1 000 000 persons) and 54 cases of GCA (RR 2. 1 cases/1 000 000 persons) have been reported. The nationwide survey allowed the characterization of 60 PMR and 35 GCA cases. Median time to the onset of first symptoms was 10 (range 2–30) and 7 (range 2–25) days for PMR and GCA, respectively. Phenotype, GCA-related ischemic complications and -large vessel vasculitis as well as therapeutic management and follow-up seemed similar according to the number of vaccine shots received and when compared to the literature data of unvaccinated population. Although rare, the short time between immunization and the onset of first symptoms of PMR and GCA suggests a temporal association. Physician should be aware of this potential vaccine-related phenomenon.https://www.tandfonline.com/doi/10.1080/21645515.2024.2334084Polymyalgia rheumaticagiant cell arteritisCOVID-19 vaccinationpharmacovigilanceclinical study |
| spellingShingle | Pierre-André Jarrot Adrien Mirouse Sébastien Ottaviani Simon Cadiou Jean-Hugues Salmon Eric Liozon Simon Parreau Martin Michaud Benjamin Terrier Pierre-Edouard Gavand Ludovic Trefond Virginie Lavoiepierre Jeremy Keraen Daniel Rekassa Bastien Bouldoires Thierry Weitten Damien Roche Antoine Poulet Caroline Charpin Vincent Grobost Marion Hermet Magali Pallure Chloe Wackenheim Ludovic Karkowski Pierre Grumet Thomas Rogier Nabil Belkefi Vincent Pestre Emilie Broquet Amélie Leurs Sophie Gautier Valérie Gras Pierre Gilet Jan Holubar Nadia Sivova Nicolas Schleinitz Jean-Marc Durand Brice Castel Alexandre Petrier Robin Arcani Baptiste Gramont Philippe Guilpain Hubert Lepidi Pierre-Jean Weiller Joelle Micallef David Saadoun Gilles Kaplanski Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey Human Vaccines & Immunotherapeutics Polymyalgia rheumatica giant cell arteritis COVID-19 vaccination pharmacovigilance clinical study |
| title | Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey |
| title_full | Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey |
| title_fullStr | Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey |
| title_full_unstemmed | Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey |
| title_short | Polymyalgia rheumatica and giant cell arteritis following COVID-19 vaccination: Results from a nationwide survey |
| title_sort | polymyalgia rheumatica and giant cell arteritis following covid 19 vaccination results from a nationwide survey |
| topic | Polymyalgia rheumatica giant cell arteritis COVID-19 vaccination pharmacovigilance clinical study |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2334084 |
| work_keys_str_mv | AT pierreandrejarrot polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT adrienmirouse polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT sebastienottaviani polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT simoncadiou polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT jeanhuguessalmon polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT ericliozon polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT simonparreau polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT martinmichaud polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT benjaminterrier polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT pierreedouardgavand polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT ludovictrefond polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT virginielavoiepierre polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT jeremykeraen polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT danielrekassa polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT bastienbouldoires polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT thierryweitten polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT damienroche polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT antoinepoulet polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT carolinecharpin polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT vincentgrobost polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT marionhermet polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT magalipallure polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT chloewackenheim polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT ludovickarkowski polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT pierregrumet polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT thomasrogier polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT nabilbelkefi polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT vincentpestre polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT emiliebroquet polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT amelieleurs polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT sophiegautier polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT valeriegras polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT pierregilet polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT janholubar polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT nadiasivova polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT nicolasschleinitz polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT jeanmarcdurand polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT bricecastel polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT alexandrepetrier polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT robinarcani polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT baptistegramont polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT philippeguilpain polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT hubertlepidi polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT pierrejeanweiller polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT joellemicallef polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT davidsaadoun polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey AT gilleskaplanski polymyalgiarheumaticaandgiantcellarteritisfollowingcovid19vaccinationresultsfromanationwidesurvey |